Menu

Top Stories

Published on Thursday, April 11, 2019

Moderated discussion: “Advancing the innovation ecosystem: Working together for patients,” in Washington, DC

Moderated discussion: “Advancing the innovation ecosystem: Working together for patients,” in Washington, DC

On April 3, 2019, Francis Collins, MD, PhD, director of the National Institutes of Health (NIH), Mikael Dolsten, MD, PhD, chief scientific officer and president, Worldwide Research, Development and Medical, Pfizer, joined in a discussion led by Susan Dentzer, visiting fellow at the Robert J. Margolis Center for Health Policy, Duke University, in Washington DC.

Photo: Francis Collins, MD, PhD, director of the NIH (left) and author Alejandro Hernandez, editorial manager of the Alpha-1 Foundation (right)

For 60 minutes, Collins, Dolsten, and Dentzer engaged in a conversation with the theme of: “Advancing the innovation ecosystem: working together for patients,” where they emphasized the need for continued collaboration between the private and public sectors, along with the patient community, in order to advance new and emerging technologies and innovative approaches for potentially life-saving treatments and new outcomes in medicine.

“We are currently living in remarkable times with amazing things happening in areas such as cancer immuno-therapy, gene therapy, and gene editing. The things that are happening right now, I had no idea they would even be possible just five or six years ago,” expressed Collins when asked about the current position “the ecosystem,” as they described the collaboration between the private and public sectors with small biotech companies; an ecosystem with symbiotic characteristics where all contributors play an important role in a tremendous team effort, in medical research.

Collins and Dolsten agreed on the importance of advocacy groups and organizations as well as the patient community, in being part of the process for better outcomes and the ability to bring new and potential treatments for various conditions to the clinic, including rare diseases, such as Alpha-1 Antitrypsin Deficiency (Alpha-1). 

“We need you, the patient community, you are the reason we have gotten this far,” said Collins.

“One of the most important resources needed for this ecosystem to strive is you, the patient. We need to line-up our resources and keep the ecosystem going, including the patient community. There is no one better to bring together what others (physicians) can do than patients: you inspire all of us,” expressed Dolsten.

The Alpha-1 Foundation applauds and supports these types of initiatives, in which patients become partners and are of vital importance for therapeutic development. 

The panel also mentioned that it is critical to spread awareness and education in the medical community, and being able to have early diagnosis and detection, while mentioning the Accelerating Medicines Partnership (AMP), a public-private partnership between the NIH, the U.S. Food and Drug Administration (FDA), multiple biopharmaceutical, and life science companies, as well as non-profit organizations to transform the current model for developing new diagnostics and treatments by jointly identifying and validating promising biological targets for therapeutics.

The ultimate goal of AMP is to increase the number of new diagnostics and therapies for patients and reduce the time and cost of developing them.

“Patient participation is critical for AMP, especially to remind us what we are doing and why-and-who we are doing it for,” said Collins, who also mentioned the Foundation for the National Institutes of Health (FNIH) as being instrumental in bringing together funds and resources from both the private and public sectors, to work in mutual collaboration in research projects that will ultimately benefit the patient community.

The Alpha-1 Foundation applauds these types of initiatives that support research and bring innovative approaches to the table for the benefit of the patient community, as we are committed to finding a cure for Alpha-1 and improving the lives of Alphas, and those affected by the condition, worldwide.

For more information, please visit the Collaboration Ecosystem website and the AMP website.


Print

Update: CSL Behring announcement on their product Zemaira

Monday, August 19, 2019
The Alpha-1 Foundation received the following communication update from CSL Behring, regarding Zemaira®, their prescription drug for augmentation therapy for the treatment of Alpha-1 Antitrypsin Deficiency (Alpha-1): "CSL Behring is...
Divider

DNA data shared in ways patients may find surprising

Tuesday, August 13, 2019
Deals between drugmakers and hospital systems to mine the genetic profiles of hospital patients are triggering concerns over the control of valuable genetic data. Drugmakers have been spending hundreds of millions of dollars for access to...
Divider

Arrowhead Pharmaceuticals doses first patient in SEQUOIA Phase 2/3 Study of ARO-AAT for treatment of Alpha-1 liver disease

Thursday, August 8, 2019
Arrowhead Pharmaceuticals Inc. announced that it has dosed the first patient in SEQUOIA (AROAAT2001), a potentially pivotal Phase 2/3 clinical study of ARO-AAT, the company’s second generation subcutaneously administered RNA interference...
Divider

CSL Behring announcement on their product Zemaira

Tuesday, August 6, 2019
Today, the Alpha-1 Foundation received the following communication from CSL Behring, regarding Zemaira®, their prescription drug for augmentation therapy for the treatment of Alpha-1 Antitrypsin Deficiency (Alpha-1). “CSL Behring...
Divider

The 28th Annual Alpha-1 National Conference: The Alpha of Tomorrow

Tuesday, July 23, 2019
Orlando, Florida was the site of the largest gathering of Alphas, caregivers, family members, researchers, industry representatives, and the Alpha-1 community in the world, as the Alpha-1 Foundation held its 28th Annual Alpha-1 National...
Divider

Save the date: Developing Therapeutics for Alpha-1 Antitrypsin Deficiency Workshop

Friday, July 19, 2019
The U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH) are sponsoring the workshop entitled "Developing Therapeutics for Alpha-1 Antitrypsin Deficiency." The federal agencies will distribute a formal...
Divider

Alpha-1 Foundation earns highest not-for-profit accreditations

Monday, July 15, 2019
The Alpha-1 Foundation earned the 2019 Platinum Seal of Transparency, the highest level of recognition offered by GuideStar, the world’s largest database and source of nonprofit information, and received a 4-star rating from Charity...
Divider

Two years have passed since the liver transplant surgery that saved Jude Ward’s life

Thursday, July 11, 2019
Almost two years have passed since Nicole and Josef Ward’s son, Jude, had a liver transplant due to Alpha-1 Antitrypsin Deficiency (Alpha-1). You can read that story by clicking here. Most people diagnosed with Alpha-1 don’t exhibit...
Divider

Dicerna to begin clinical development of DCR-A1AT for treatment of patients with Alpha-1-associated liver disease

Monday, July 8, 2019
Dicerna Pharmaceuticals, Inc. announced it submitted a Clinical Trial Authorization (CTA) application to the Swedish Medical Products Agency (MPA) to conduct a first-in-human Phase 1/2 study of DCR-A1AT, an investigational therapy from the...
Divider

FDA grants fast track to Alpha-1-related liver disease drug

Friday, June 28, 2019
Arrowhead Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation to ARO-AAT, the company’s second-generation subcutaneously administered RNA interference (RNAi) therapeutic being...
Divider

Watch the 28th Annual Alpha-1 National Conference from home

Tuesday, June 18, 2019
The Annual Alpha-1 National Conference is the largest annual gathering of Alphas, their families, leading healthcare professionals, including researchers, physicians, scientists, respiratory therapists, nurse practitioners, and industry...
Divider

The Annual Alpha-1 National Conference: The largest gathering of Alphas

Tuesday, June 18, 2019
The city of Orlando, Florida, will be the site of the largest gathering of Alphas, caregivers, family members, researchers, industry representatives, and the Alpha-1 community at large, as the Alpha-1 Foundation holds its 28th Annual Alpha-1...
Divider
12345678910Last

Article Search

Enter keywords in text box and click Search button for results.

Archive